Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5626991 | 0.92 | KCNH2 (0.55) | KCNH2 | |
| SCHEMBL3215282 | 0.80 | KCNH2 (0.40) | KCNH2NR1H4 | |
| SCHEMBL2767348 | 0.80 | KCNH2 (0.68) | KCNH2 | |
| SCHEMBL3469480 | 0.80 | KCNH2 (0.68) | KCNH2 | |
| SCHEMBL2767059 | 0.80 | KCNH2 (0.68) | KCNH2 | |
| SCHEMBL3209294 | 0.79 | KCNH2 (0.40) | KCNH2NR1H4 | |
| SCHEMBL2939431 | 0.78 | KCNH2 (0.54) | KCNH2 | |
| SCHEMBL13244842 | 0.74 | KCNH2 (0.65) | KCNH2 | |
| SCHEMBL11999874 | 0.73 | HSD11B1 (0.38) | NR1H4 | |
| SCHEMBL2799351 | 0.73 | PIK3CA (0.37) | KCNH2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732460-B2 | Heterocyclic compounds, their preparation and their use as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | MRPL21, NACA, NISCH | KCNH2 1599/4885NR1H4 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.